Asymmetrex Sponsors Podcast on "Counting Stem Cells for a New Era of Medicine"
BOSTON (PRWEB) November 06, 2019
In October, Massachusetts stem cell biotechnology company Asymmetrex launched a new podcast to provide information to patients about a poorly disclosed deficiency in stem cell treatments. Throughout stem cell medical practice, stem cell treatments are given without knowing the dose of the treating stem cells. This problem affects all patients receiving stem cell treatments, including patients receiving approved treatments in routine clinical practice, patients volunteering for experimental treatments in FDA-authorized clinical trials, and patients obtaining unapproved treatments in private stem cell clinics.
The costs and dangers of unknown stem cell dose in treatments are significant. Stem cell clinical trials cannot be interpreted without knowing the treatment dose, leading to huge wastes of both federal and private clinical research dollars. In the case of manufactured stem cells, many treatments may contain very few or no stem cells at all. It is impossible for doctors to improve treatments without knowing the stem cell dose. Stem cell donors for approved treatments like blood stem cell transplantation are scarce. Knowing the stem cell dose would allow doctors to know when a treatment sample has enough stem cells to treat more than one patient; or when it does not have enough to treat even a single patient. In the second case, not knowing the stem cell dose can result in the death of children treated for leukemia when unknowingly they receive an umbilical cord blood transplant with too few blood stem cells to save them.
Earlier this year, the FDA recognized the pressing need for stem cell dose in stem cell medicine. The agencys Standards Coordinating Body for Regenerative Medicine (SCB) listed stem cell dose determination as a priority for needed standards for stem cell medicine. Dose is a fundamental principle for the discovery, development, and administration of quality medicines. Asymmetrex Director James L. Sherley, M.D., Ph.D., who is featured in the new podcast, says that, Dose is essential for stem cell medicine as well. The new podcast has the goal of informing the end users of stem cell treatments: the patients, their doctors, their families, and their advocates, including the FDA. When the people most impacted by these treatments understand that knowing the dose of stem cells is just as important as knowing the dose of their other medicines, they will be empowered to demand this essential certification of the integrity of their stem cell treatments.
The first episode of the podcast, Counting Stem Cells For A New Era Of Medicine, aired online on October 17. The third episode of the biweekly, 6-episode series is scheduled for airing November 12. Each episode features an interview of Asymmetrex Director Sherley by podcast producer Jordan Rich. Mr. Rich guides Dr. Sherley through a discussion of questions that reveal the current challenges that Asymmetrex is addressing to achieve full adoption of stem cell dose as a routine practice in stem cell medicine. The series also highlights other significant applications for stem cell counting in drug development and environmental health science. In conjunction with this educational effort, the company is also sponsoring a study on its website to evaluate the current state of public, academic, and industry knowledge of coming changes in stem cell medicine related to the adoption of stem cell dose.
About Asymmetrex
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the AlphaSTEM Test) for use in stem cell transplantation therapies and pre-clinical drug evaluations.
Share article on social media or email:
See the rest here:
New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments - PR Web
- Heres How Fasting Benefits Your Mental and Physical Wellbeing - News18 - October 4th, 2022
- Asymmetrex Gives First Cell Culture Core Facility Introduction to Online Rapid Stem Cell Counting in the Institute for Applied Life Sciences at... - September 25th, 2022
- Asymmetrex's Introduction of Online Calculators for Determination of the Dosage of Therapeutic Stem Cells Announced as a Reformation in Stem Cell... - September 16th, 2022
- UMass Dartmouth awarded $750000 Massachusetts Life Science grant to diversify the field - New Bedford Guide - September 16th, 2022
- ALS Thought Leaders Weigh in Ahead of Second Amylyx Adcomm - BioSpace - September 8th, 2022
- Scientists convert kidney to universal O blood type - Freethink - August 30th, 2022
- Case Study: SARS-CoV-2 Virus Infecting the Inner Ear - Victoria News - August 14th, 2022
- Evidence Is Growing That LSD Improves Learning and Memory - Futurism - August 14th, 2022
- Rice University: Rice, Baylor developing implants to heal heart attack injuries | India Education | Latest Education News | Global Educational News |... - August 14th, 2022
- Iconic everyday inventions and the women behind them - YourStory - August 14th, 2022
- Head to Head Analysis: VolitionRx (NYSE:VNRX) vs. Intellia Therapeutics (NASDAQ:NTLA) - Defense World - August 14th, 2022
- Man who saved life as stem cell donor urges others to help his friend find a match after five-year search - Lancashire Evening Post - August 5th, 2022
- The 3D Cell Culture Market is expected to reach a value of USD 3721.86 Million by 2027, at a CAGR of 13.4% (2021 2027) - Digital Journal - August 5th, 2022
- Flow Cytometry Market is expected to reach a value of USD 11467.80 Million by 2027, at a CAGR of 8.88% over the forecast period (2021 2027) - Digital... - July 27th, 2022
- Stem Cells Market Competitive Insights And Global Outlook 2022 To 2027 Vcanbio, Boyalife, Beikebiotech, Thermo Fisher Scientific (Massachusetts, US),... - July 11th, 2022
- Seven UMass Amherst Faculty Members Receive NSF CAREER Awards in 2021-22 Academic Year - UMass News and Media Relations - July 11th, 2022
- BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal - GuruFocus.com - June 22nd, 2022
- Asymmetrex Presents New Developments in its Rapid Stem Cell Counting Technology at the ARMI|BioFabUSA Meeting in the Millyard on Regenerative Medicine... - June 13th, 2022
- Investigators Seek to Push Combination Therapy to the Front-line Treatment of aGVHD - OncLive - June 4th, 2022
- Stem Cells Market 2022 Industry Analysis, Segmentation, Share, Size, Opportunities and Forecast to 2027 The Greater Binghamton Business Journal - The... - June 4th, 2022
- Sheldon Krimsky, Who Warned of Profit Motive in Science, Dies at 80 - The New York Times - May 15th, 2022
- We met during cancer treatments, fell in love and got married - New York Post - May 15th, 2022
- Ticking time bombs of DNA mutation may dictate when animals die - Livescience.com - May 2nd, 2022
- Sen. Orrin Hatch's legacy tracks the GOP's evolution on health - Wisconsin Public Radio - May 2nd, 2022
- Emerging interactions between skin stem cells and their ... - April 6th, 2022
- Priothera Receives R&D Innovation Loan from Bpifrance - PR Newswire - April 6th, 2022
- What is Regeneration? review: A dive into the science of regrowth - New Scientist - April 6th, 2022
- 5 FDA decisions to watch in the second quarter - BioPharma Dive - April 6th, 2022
- Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners - The New York Academy of Sciences - April 6th, 2022
- MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults... - March 25th, 2022
- January 2022: 2021 Papers of the year - Environmental Factor Newsletter - January 5th, 2022
- Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL - www.oncnursingnews.com/ - January 5th, 2022
- Stem cells: Sources, types, and uses - Medical News Today - December 24th, 2021
- cGVHD Paradigm Gains Systemic Options Beyond Steroids, But Real-World Data Are Required - OncLive - October 28th, 2021
- Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting - PRNewswire - June 23rd, 2021
- Infertility: Men account for at least half of cases. So why have women shouldered the blame? - The Irish Times - June 23rd, 2021
- On systemic sources of early life stress, and empathetic responses - MIT News - June 6th, 2021
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily - February 1st, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium - GlobeNewswire - February 1st, 2021
- NurOwn May Be Given to Early ALS Patients in US Who Finished Phase... - ALS News Today - December 20th, 2020
- Be Biopharma debuts with $52M to advance engineered B-cell therapies - FierceBiotech - October 24th, 2020
- Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans - Cancer Therapy Advisor - September 5th, 2020
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise - July 2nd, 2020
- Startup targets glioblastoma tumors with CAR-T therapy - FierceBiotech - May 28th, 2020
- Infrared Laser Treatment of TBI, PTSD, and Depression: An Expert Perspective - Psychiatry Advisor - April 3rd, 2020
- 10 Of The Biggest World Revelations In The 21st Century - World Atlas - February 29th, 2020
- Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 - BioSpace - January 10th, 2020
- Firm adds a new wrinkle to anti-aging products - Williamson Daily News - January 5th, 2020
- Top Emerging Technologies of the Year - Technowize - December 29th, 2019
- Exercise found to block chronic inflammation in mice - Harvard Gazette - November 9th, 2019
- Arkuda bags $44M to target progranulin and head off inherited dementia - FierceBiotech - November 9th, 2019
- New study reveals why breast cancer spreads to the brain - USC News - October 23rd, 2019
- Comparison of Merus N.V. (MRUS) and Sage Therapeutics Inc. (NASDAQ:SAGE) - MS Wkly - October 23rd, 2019
- Reviewing Cellectis S.A. (CLLS)'s and Magenta Therapeutics Inc. (NASDAQ:MGTA)'s results - MS Wkly - October 23rd, 2019
- Massachusetts Stem Cells | Stem Cell TV - September 10th, 2019
- Chronic variable stress activates hematopoietic stem cells ... - April 12th, 2019
- Boston, MA, Stem Cell Transplant, Weston, Nantucket ... - January 10th, 2019
- Cloning/Embryonic Stem Cells - National Human Genome ... - July 5th, 2018
- Alternate Methods for Preparing Pluripotent Stem Cells ... - September 25th, 2017
- Doubts raised about CRISPR gene-editing study in human embryos - Nature.com - September 2nd, 2017
- For Lowell native, stem cell match becomes a match as friends - Lowell Sun - September 2nd, 2017
- Lymphoma Patient's Brain Tumor Disappeared After She Received JCAR017, Study Reports - Lymphoma News Today - September 2nd, 2017
- Asymmetrex Introduces New Contract Service For Producing ... - PR Web (press release) - August 29th, 2017
- ORGANOID - Science Magazine - August 27th, 2017
- Current humanized mice not good models for studying stem cell transplants, say researchers - Scope (blog) - August 27th, 2017
- Mouse Model of Human Immune System Inadequate for Stem Cell ... - Technology Networks - August 27th, 2017
- CRISPR fixes disease gene in viable human embryos - Nature.com - August 6th, 2017
- X4 joins hands with Yale on rare disease program - FierceBiotech - August 6th, 2017
- TGF-1: ALS Astrocytes' Secret Sauce? - ALS Research Forum - August 6th, 2017
- From Stem Cells to Human Development - September 2016 ... - December 4th, 2016
- Stem cell controversy - Wikipedia - December 1st, 2016
- What Are Stem Cells? - Massachusetts General Hospital ... - November 22nd, 2016
- New England Cord Blood Bank - Cord Blood and Cord Tissue ... - November 22nd, 2016
- Stem-cell-based therapy promising for treatment of breast ... - September 26th, 2016
- Stem Cell FAQ - Massachusetts General Hospital, Boston, MA - July 27th, 2016
- Stem Cell Facts - University of Massachusetts Medical School - July 27th, 2016
- Scientists engineer toxin-secreting stem cells to treat ... - October 19th, 2015
- Cloning/Embryonic Stem Cells - Genome.gov - October 19th, 2015
- Biomedical engineer developing nanomaterial for healing broken bones - March 18th, 2015
- Researchers identify a vital protein that can determine head and brain development - March 13th, 2015